97497987 - COMPUTING THE FUTURE OF MEDICINE

Information

• Trademark
• 97497987

• Source

• Serial Number

  97497987

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 9 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  July 11, 2022
  2 years ago

• Transaction Date

  October 09, 2024
  2 months ago

• Status Date

  October 09, 2024
  2 months ago

• Published for Opposition Date

  February 13, 2024
  10 months ago

• Location Date

  April 09, 2024
  8 months ago

• Status Code

  690

• Current Location

  INTENT TO USE SECTION

  Employee Name

  WOOD, CAROLINE

• Attorney Docket Number

  210309.00025

  Attorney Name

  Anna King

  Law Office Assigned Location Code

  M10

• Owners

  • E-THERAPEUTICS PLC

Case File Statements

• GS0401: Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
• GS0091: Downloadable and recorded computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; downloadable computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; downloadable databases in the field of pharmaceuticals, medicines and drug discovery; electronic databases recorded on computer media, for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded computer platform software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; downloadable and recorded computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery
• GS0051: Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
• GS0421: Scientific research and development; pharmaceutical research and development services; scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; human genetic research; scientific and technical data analysis in the field of pharmaceuticals, medicines and drug discovery; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software; design, development, creation and maintenance of computational computer software platforms; design, development, creation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models; design of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS); Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and generating pharmaceutical and medical preparations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid

Case File Event Statements

• 7/29/2022 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 7/14/2022 - 2 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 4/19/2023 - a year ago

  3 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI

• 4/25/2023 - a year ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 4/27/2023 - a year ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 4/27/2023 - a year ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 4/27/2023 - a year ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 6/26/2023 - a year ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 11/30/2023 - a year ago

  9 - ASSIGNED TO LIE Type: ALIE

• 11/30/2023 - a year ago

  10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 11/30/2023 - a year ago

  11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 1/5/2024 - 11 months ago

  12 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 1/5/2024 - 11 months ago

  13 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 1/5/2024 - 11 months ago

  14 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 1/5/2024 - 11 months ago

  15 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 1/24/2024 - 11 months ago

  17 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 2/13/2024 - 10 months ago

  18 - PUBLISHED FOR OPPOSITION Type: PUBO

• 2/13/2024 - 10 months ago

  19 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 1/7/2024 - 11 months ago

  16 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 4/9/2024 - 8 months ago

  20 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 9/26/2024 - 2 months ago

  21 - TEAS DELETE 1(B) BASIS RECEIVED Type: D1BR

• 10/9/2024 - 2 months ago

  22 - NOTICE OF ALLOWANCE CANCELLED Type: IUCN

• 10/9/2024 - 2 months ago

  23 - 1(B) BASIS DELETED; PROCEED TO REGISTRATION Type: DP1B